{
    "nctId": "NCT01603303",
    "briefTitle": "Preventing Sexual Dysfunction With Aromatase Inhibitors",
    "officialTitle": "Preventing Sexual Dysfunction in Women on Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 187,
    "primaryOutcomeMeasure": "Sexual Dysfunction Rate Reduction",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Diagnosis of Stage 0 to III breast cancer\n2. Age over 18 years\n3. Began adjuvant therapy with an aromatase inhibitor 12 to 18 months before survey sent out (Benchmark Survey only)\n4. Was prescribed adjuvant therapy with an AI (prior chemotherapy or tamoxifen OK) in past 2 to 4 weeks (Randomized Trial only)\n5. Had sexual activity at least once in past 12 months (Randomized Trial Study only)\n6. Has been in a stable sexual relationship of at least 6 months' duration (Randomized Trial study only)\n\nExclusion Criteria:\n\n1. Women using systemic or vaginal estrogen, testosterone, or dehydroepiandrosterone (DHEA) during the Randomized Trial study will be excluded\n2. Women using systemic or vaginal estrogen, testosterone, or dehydroepiandrosterone (DHEA) in the 12 months preceding the Benchmark Survey Study will be excluded\n3. Has distant metastases\n4. Cannot read or speak English well enough to understand materials and complete questionnaires\n5. No access to the internet in a private location",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}